Other OTC - Delayed Quote • USD
Bellerophon Therapeutics, Inc. (BLPH)
As of 12:32 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.53 | 0.27 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 1 |
| Avg. Estimate | -- | -- | 5.64M | -- |
| Low Estimate | -- | -- | 5.64M | -- |
| High Estimate | -- | -- | 5.64M | -- |
| Year Ago Sales | -- | -- | -- | 5.64M |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.49 | -0.42 | -0.44 |
| EPS Actual | -0.53 | 0.27 | -0.42 | -0.16 |
| Difference | -0.05 | 0.76 | 0 | 0.28 |
| Surprise % | -10.40% | 155.10% | 0.00% | 63.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.42 | 0 | -1 | -1.82 |
| 30 Days Ago | -0.42 | 0 | -1 | -1.82 |
| 60 Days Ago | -0.42 | 0 | -1 | -1.82 |
| 90 Days Ago | -0.42 | 0 | -1 | -1.82 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BLPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | 472.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 6/6/2023 |
| Downgrade | Laidlaw & Co.: Buy to Hold | 6/6/2023 |
| Initiated | Laidlaw & Co.: Buy | 5/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 4/4/2023 |
| Initiated | Jefferies: Buy | 8/11/2020 |
| Initiated | Maxim Group: Buy | 1/24/2019 |
Related Tickers
SQZB SQZ Biotechnologies Company
0.0483
0.00%
APTO Aptose Biosciences Inc.
1.2500
-1.57%
PULM Pulmatrix, Inc.
1.9900
+2.05%
AKTX Akari Therapeutics, Plc
1.1900
+1.71%
EVLO Evelo Biosciences, Inc.
0.0360
-28.00%
BCEL Atreca, Inc.
0.0790
+3.81%
XBIO Xenetic Biosciences, Inc.
4.2000
+5.00%
BTTX Better Therapeutics, Inc.
0.0062
-21.45%
WINT Windtree Therapeutics, Inc.
0.3559
+6.37%
CMRA Comera Life Sciences Holdings, Inc.
0.0410
0.00%